BioCentury
ARTICLE | Clinical News

Bavencio, Inlyta combo meets PFS endpoint in first-line RCC

September 11, 2018 10:08 PM UTC

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) said Bavencio avelumab plus Inlyta axitinib met the primary endpoint of improving progression-free survival vs. Sutent sunitinib in the Phase III JAVELIN Renal 101 trial to treat previously untreated advanced renal cell carcinoma.

According to an interim analysis by an IDMC, Bavencio plus Inlyta significantly improved PFS vs. Sutent in patients with PD-L1-positive tumors, the primary endpoint population, and in the entire patient population regardless of PD-L1 tumor expression, a secondary endpoint. Details were not disclosed...

BCIQ Company Profiles

Merck KGaA

Pfizer Inc.